Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
Authors
Keywords
-
Journal
European Journal of Preventive Cardiology
Volume 23, Issue 7, Pages 758-768
Publisher
SAGE Publications
Online
2015-07-31
DOI
10.1177/2047487315598709
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist
- (2014) J. Hoekman et al. Clinical Journal of the American Society of Nephrology
- Endothelin Antagonists in Diabetic Nephropathy: Back to Basics
- (2014) K. Chandrashekar et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
- (2014) D. de Zeeuw et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Endothelin and endothelin antagonists in chronic kidney disease
- (2014) Donald E Kohan et al. KIDNEY INTERNATIONAL
- A novel approach for establishing cardiovascular drug efficacy
- (2014) Hiddo. J. Lambers Heerspink et al. NATURE REVIEWS DRUG DISCOVERY
- Changes in Diabetes-Related Complications in the United States, 1990–2010
- (2014) Edward W. Gregg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers
- (2013) P A Smink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers
- (2013) PA Smink et al. European Journal of Preventive Cardiology
- Risk prediction models: II. External validation, model updating, and impact assessment
- (2012) Karel G M Moons et al. HEART
- Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD
- (2012) N. Dhaun et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
- (2011) D. E. Kohan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Enrichment of Clinical Study Populations
- (2010) R Temple CLINICAL PHARMACOLOGY & THERAPEUTICS
- Comparison of Different Measures of Urinary Protein Excretion for Prediction of Renal Events
- (2010) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
- (2009) R. R. Wenzel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
- (2009) Michael A Weber et al. LANCET
- Defining the optimal dose of a new drug: a crucial decision
- (2009) Hiddo Lambers Heerspink et al. Nature Reviews Nephrology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search